Dr. Steve Antoine discusses the STRONG-HF trial with co-host, Dr. Liz Wang.
0:00-2:37: Introduction
2:38-7:54: STRONG-HF trial overview
7:55-11:44: Overall thoughts
11:45-13:45: Baseline therapies
13:46-19:59: Discussion of titration and follow up in the trial
20:00-21:22: Ejection fraction considerations
21:23-23:22: Final thoughts
23:23-23:58: Closing
References:
STRONG-HF
Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938-1952. doi:10.1016/S0140-6736(22)02076-1
TOPCAT
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. doi:10.1056/NEJMoa1313731
CardioScripts 